Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
A PHASE1/PHASE2 clinical study on Leukemia, Lymphocytic, Chronic, B-Cell, this trial is completed. The trial is conducted by Arbeitsgemeinschaft medikamentoese Tumortherapie and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Celgene Corporation
- Roche Pharma AG
For direct contact, visit the study record on ClinicalTrials.gov .